EMA makes significant changes to paediatric drugs guide; reissues draft for consultation
This article was originally published in SRA
Executive Summary
The European Medicines Agency has reissued for consultation a draft guideline on the development of paediatric medicines after making important revisions to the initial document in light of feedback from stakeholders1. The new draft guideline is accompanied by a 331-page document in which the EMA outlines the concerns it had received from stakeholders and how it intends to deal with them2.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.